SAB Biotherapeutics, Inc.

SABSNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

▼ 100.0% YoY

Net Income

$13.3M

▲ 138.9% YoY

EPS

$-0.79

▲ 78.5% YoY

Cash

$10.5M

▲ 18.0% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.